Bio-Techne Q4 FY2025 Results: 3% Organic Revenue Growth, $317.0M Revenue, and $0.53 Adjusted EPS

Bio-Techne reported Q4 FY2025 results with organic revenue increasing 3% to $317.0 million and full-year organic revenue up 5% to $1.2 billion. The Protein Sciences segment saw 4% organic growth, driven by strong performance in proteomic analytic and cell therapy growth pillars. The company also announced the divestiture of Exosome Diagnostics business to focus on non-CLIA based product lines.